Litcius/Paper detail

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

Till Koch, Christine Dahlke, Anahita Fathi, Alexandra Kupke, Verena Krähling, Nisreen M.A. Okba, Sandro Halwe, Cornelius Rohde, Markus Eickmann, Asisa Volz, Thomas Hesterkamp, Alen Jambrecina, Saskia Borregaard, My Linh Ly, Madeleine E. Zinser, Etienne Bartels, Joseph S H Poetsch, Reza Neumann, Robert Fux, Stefan Schmiedel, Ansgar W. Lohse, Bart L. Haagmans, Gerd Sutter, Stephan Becker, Marylyn M. Addo

2020The Lancet Infectious Diseases171 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityVirologyVacciniaModified vaccinia AnkaraMedicineOpen labelMiddle East respiratory syndromeCoronavirus disease 2019 (COVID-19)BiologyClinical trialImmunologyAntigenGeneInfectious disease (medical specialty)Internal medicineDiseaseRecombinant DNABiochemistrySARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesVirology and Viral Diseases
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial | Litcius